[Answered] Dry powder inhalers (DPIs): A) use fluorocarbon propellants B) deliver liquid aerosol medication ...

This topic contains a solution. Click here to go to the answer

Author Question: Dry powder inhalers (DPIs): A) use fluorocarbon propellants B) deliver liquid aerosol medication ... (Read 76 times)

Charlie

Hero Member
Posts: 640

on: Jul 16, 2018

Dry powder inhalers (DPIs):
A) use fluorocarbon propellants
B) deliver liquid aerosol medication
C) require a pressurized-gas source
D) none of the above

Question 2

As the radius of a bubble, or alveolus, decreases, the surface tensionA) fluctuates unpredictablyB) stays the same
C) decreases
D) increases

Need homework help now?

Ask unlimited questions for free

Ask a Question

Marked as best answer by a Subject Expert

jaaaaaaa

Sr. Member
Posts: 341

Reply #1 on: Jul 16, 2018

Answer to Question 1

D

Answer to Question 2

D

Charlie

Member
Posts: 640

Reply 2 on: Jul 16, 2018

Excellent

cdmart10

Member
Posts: 332

Reply 3 on: Yesterday

Great answer, keep it coming

« previous next »

Did you know?

Acetaminophen (Tylenol) in overdose can seriously damage the liver. It should never be taken by people who use alcohol heavily; it can result in severe liver damage and even a condition requiring a liver transplant.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

Though newer “smart” infusion pumps are increasingly becoming more sophisticated, they cannot prevent all programming and administration errors. Health care professionals that use smart infusion pumps must still practice the rights of medication administration and have other professionals double-check all high-risk infusions.

Did you know?

Your chance of developing a kidney stone is 1 in 10. In recent years, approximately 3.7 million people in the United States were diagnosed with a kidney disease.

Did you know?

In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.